GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Operating Margin %

Arch Therapeutics (Arch Therapeutics) Operating Margin % : -2,740.63% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Arch Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-0.88 Mil. Arch Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.03 Mil. Therefore, Arch Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was -2,740.63%.

The historical rank and industry rank for Arch Therapeutics's Operating Margin % or its related term are showing as below:

ARTH' s Operating Margin % Range Over the Past 10 Years
Min: -53141.67   Med: -35681.25   Max: -3599.24
Current: -3599.24


ARTH's Operating Margin % is ranked worse than
84.91% of 1027 companies
in the Biotechnology industry
Industry Median: -161.26 vs ARTH: -3599.24

Arch Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Arch Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-0.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.72 Mil.


Arch Therapeutics Operating Margin % Historical Data

The historical data trend for Arch Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Operating Margin % Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -53,141.67 -35,681.25 -6,636.84

Arch Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,382.35 -7,800.00 -3,322.50 -3,250.00 -2,740.63

Competitive Comparison of Arch Therapeutics's Operating Margin %

For the Biotechnology subindustry, Arch Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Operating Margin % falls into.



Arch Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Arch Therapeutics's Operating Margin % for the fiscal year that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (A: Sep. 2023 ) / Revenue (A: Sep. 2023 )
=-5.044 / 0.076
=-6,636.84 %

Arch Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-0.877 / 0.032
=-2,740.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Therapeutics  (OTCPK:ARTH) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Arch Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Therapeutics (Arch Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
Terrence W Norchi director, officer: President & CEO C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams officer: CFO and Treasurer 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen officer: Vice President, Sales C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat director
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis officer: CFO & Treasurer
Avtar S Dhillon director C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal director 100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber officer: Chief Financial Officer C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter officer: Chief Operating Officer C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616

Arch Therapeutics (Arch Therapeutics) Headlines

From GuruFocus

Arch Therapeutics Announces Appointment of Guy Fish to the Board

By GuruFocusNews GuruFocusNews 01-04-2022